{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Error analysis for the type of examples that Stop words get wrong compared to the baseline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "%autoreload\n",
    "import os\n",
    "from sys import path\n",
    "import re\n",
    "import pandas as pd\n",
    "path.append('../../..')\n",
    "import numpy as np\n",
    "from scipy.stats import ttest_rel\n",
    "from relation_extraction.data.converters.converter_ddi import relation_dict\n",
    "output_path = '/scratch/geeticka/relation-extraction-result/ddi-analyze/'\n",
    "def res(path): return os.path.join(output_path, path)\n",
    "original_sentences_path = os.path.join('/scratch/geeticka/relation-extraction-result/ddi-analyze/test_original.txt')\n",
    "stop_words_sentences_path = os.path.join('/crimea/geeticka/data/relation_extraction/ddi/pre-processed/punct_stop_digit/test_punct_stop_digit.txt')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{0: 'advise', 1: 'effect', 2: 'mechanism', 3: 'int', 4: 'none'}"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "relation_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_answers_line(line):\n",
    "    linenum, relation = line.strip().split()\n",
    "    return linenum, relation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def asstring(list_of_strings):\n",
    "    return \" \".join(list_of_strings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_sentence_and_entities(line):\n",
    "    line = line.strip().split()\n",
    "    sentence = line[5:]\n",
    "    relation = relation_dict[int(line[0])]\n",
    "    entity1_idx = (int(line[1]), int(line[2]))\n",
    "    entity2_idx = (int(line[3]), int(line[4]))\n",
    "    entity1 = sentence[entity1_idx[0] : entity1_idx[1] + 1]\n",
    "    entity2 = sentence[entity2_idx[0] : entity2_idx[1] + 1]\n",
    "    \n",
    "    return relation, asstring(entity1), asstring(entity2), asstring(sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "needed_linenum_and_relation = {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(res(\"answers_for_dev-stop-word.txt\")) as textfile1, open(res('answers_for_dev-baseline.txt')) as textfile2, \\\n",
    "open(res('answers_for_dev-baseline_gold.txt')) as textfile3: \n",
    "    for x, y, z in zip(textfile1, textfile2, textfile3):\n",
    "        linenum, stop_words_relation = read_answers_line(x)\n",
    "        _, baseline_relation = read_answers_line(y)\n",
    "        _, gold_relation = read_answers_line(z)\n",
    "        if baseline_relation == gold_relation and stop_words_relation != gold_relation: # punct digit making mistakes\n",
    "            needed_linenum_and_relation[int(linenum) - 1] = (baseline_relation, stop_words_relation)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "267"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list(needed_linenum_and_relation.keys()))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Remember that baseline is correct here so the first relation listed is the correct one, unlike in the i2b2 notebook where the order is reversed because baseline is the incorrect one there"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "interaction = 0; mechanism = 0; advice = 0; effect = 0; none = 0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "We print the baseline first and then the stop words version. Gold relation corresponds to baseline\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t terbinafine, terbinafine \t tolbutamide, tolbutamide \n",
      "Sentences: \n",
      "\tIn vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . \n",
      "\t vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t terbinafine, terbinafine \t ethinylestradiol, ethinylestradiol \n",
      "Sentences: \n",
      "\tIn vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . \n",
      "\t vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t terbinafine, terbinafine \t ethoxycoumarin, ethoxycoumarin \n",
      "Sentences: \n",
      "\tIn vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . \n",
      "\t vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t terbinafine, terbinafine \t digoxin, digoxin \n",
      "Sentences: \n",
      "\tIn vivo drug - drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin . \n",
      "\t vivo drug drug interaction studies conducted normal volunteer subjects showed terbinafine affect clearance antipyrine digoxin\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t terbinafine, terbinafine \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tThere have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin , however , a causal relationship between LAMISIL Tablets and these changes has not been established . \n",
      "\t spontaneous reports increase decrease prothrombin times patients concomitantly taking oral terbinafine warfarin causal relationship LAMISIL Tablets changes established\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Terbinafine, Terbinafine \t rifampin, rifampin \n",
      "Sentences: \n",
      "\tTerbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . \n",
      "\t Terbinafine clearance increased NUMBER rifampin CyP450 enzyme inducer decreased NUMBER cimetidine CyP450 enzyme inhibitor\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Terbinafine, Terbinafine \t cimetidine, cimetidine \n",
      "Sentences: \n",
      "\tTerbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . \n",
      "\t Terbinafine clearance increased NUMBER rifampin CyP450 enzyme inducer decreased NUMBER cimetidine CyP450 enzyme inhibitor\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t gemfibrozil, gemfibrozil \t rosiglitazone, rosiglitazone \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t inhibitor CYP2C8 gemfibrozil increase AUC rosiglitazone inducer CYP2C8 rifampin decrease AUC rosiglitazone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t rifampin, rifampin \t rosiglitazone, rosiglitazone \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t inhibitor CYP2C8 gemfibrozil increase AUC rosiglitazone inducer CYP2C8 rifampin decrease AUC rosiglitazone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Ritalin, Ritalin \t diphenylhydantoin, diphenylhydantoin \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t Human pharmacologic studies shown Ritalin inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Ritalin, Ritalin \t primidone, primidone \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t Human pharmacologic studies shown Ritalin inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t methylphenidate, methylphenidate \t clonidine, clonidine \n",
      "Sentences: \n",
      "\tThe safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated . \n",
      "\t safety methylphenidate combination clonidine centrally acting alpha-2 agonists systemically evaluated\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t phenytoin, phenytoin \t phenytoin, phenytoin \n",
      "Sentences: \n",
      "\tTrimethoprim , given at a common clinical dosage , increased the phenytoin half - life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % . \n",
      "\t Trimethoprim given common clinical dosage increased phenytoin half life NUMBER decreased phenytoin metabolic clearance rate NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t AGGRASTAT, AGGRASTAT \t heparin, heparin \n",
      "Sentences: \n",
      "\tThe use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see \n",
      "\t use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t AGGRASTAT, AGGRASTAT \t aspirin, aspirin \n",
      "Sentences: \n",
      "\tThe use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see \n",
      "\t use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, phenytoin \t Mexitil, Mexitil \n",
      "Sentences: \n",
      "\tWhen phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . \n",
      "\t phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Mexitil, Mexitil \t Mexitil, Mexitil \n",
      "Sentences: \n",
      "\tConcurrent administration of cimetidine and Mexitil has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; \n",
      "\t Concurrent administration cimetidine Mexitil reported increase decrease leave unchanged Mexitil plasma levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Mexitil, Mexitil \t digoxin, digoxin \n",
      "Sentences: \n",
      "\tMexitil does not alter serum digoxin levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . \n",
      "\t Mexitil alter serum digoxin levels magnesium aluminum hydroxide treat gastrointestinal symptoms Mexitil reported lower serum digoxin levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Mexitil, Mexitil \t theophylline, theophylline \n",
      "Sentences: \n",
      "\tConcurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . \n",
      "\t Concurrent use Mexitil theophylline lead increased plasma theophylline levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Mexitil, Mexitil \t theophylline, theophylline \n",
      "Sentences: \n",
      "\tConcurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . \n",
      "\t Concurrent use Mexitil theophylline lead increased plasma theophylline levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t theophylline, theophylline \t theophylline, theophylline \n",
      "Sentences: \n",
      "\tConcurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . \n",
      "\t Concurrent use Mexitil theophylline lead increased plasma theophylline levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t Mexitil, Mexitil \t theophylline, theophylline \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t increase observed test point second day starting Mexitil Theophylline plasma levels returned pre- Mexitil values NUMBER hours discontinuing Mexitil Mexitil theophylline concurrently theophylline blood levels monitored particularly Mexitil dose changed\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t GH, GH \t cyclosporin, cyclosporin \n",
      "Sentences: \n",
      "\tThese data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) . \n",
      "\t data suggest GH administration alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t DIPRIVAN, DIPRIVAN \t neuromuscular blocking agents, neuromuscular blocking agents \n",
      "Sentences: \n",
      "\tDIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) . \n",
      "\t DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t DIPRIVAN, DIPRIVAN \t nondepolarizing muscle relaxants, nondepolarizing muscle relaxants \n",
      "Sentences: \n",
      "\tDIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) . \n",
      "\t DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t antacids, antacids \t SKELID, SKELID \n",
      "Sentences: \n",
      "\tThe bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . \n",
      "\t bioavailability SKELID decreased NUMBER calcium calcium SKELID administered time NUMBER aluminum magnesium -containing antacids administered NUMBER hour SKELID\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t tiludronate, tiludronate \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tIn vitro studies show that tiludronate does not displace warfarin from its binding site on protein . \n",
      "\t vitro studies tiludronate displace warfarin binding site protein\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Sanctura, Sanctura \t digoxin, digoxin \n",
      "Sentences: \n",
      "\tDrugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . \n",
      "\t Drugs Eliminated Active Tubular Secretion studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Sanctura, Sanctura \t tenofovir, tenofovir \n",
      "Sentences: \n",
      "\tDrugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . \n",
      "\t Drugs Eliminated Active Tubular Secretion studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t enflurane, enflurane \t oxygen, oxygen \n",
      "Sentences: \n",
      "\tIsoflurane and enflurane ( administered with nitrous oxide / oxygen to achieve 1.25 M.C. \n",
      "\t Isoflurane enflurane administered nitrous oxide oxygen achieve NUMBER M.C.\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t propranolol, propranolol \t phenothiazines, phenothiazines \n",
      "Sentences: \n",
      "\tConcomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs . \n",
      "\t Concomitant administration propranolol phenothiazines results increased plasma levels drugs\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Streptase, Streptase \t Streptokinase, Streptokinase \n",
      "Sentences: \n",
      "\tThe interaction of Streptase , Streptokinase , with other drugs has not been well studied . \n",
      "\t interaction Streptase Streptokinase drugs studied\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptase, Streptase \t antiplatelet agents, antiplatelet agents \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use Anticoagulants Antiplatelet Agents Streptase Streptokinase combination antiplatelet agents anticoagulants cause bleeding complications\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptokinase, Streptokinase \t antiplatelet agents, antiplatelet agents \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use Anticoagulants Antiplatelet Agents Streptase Streptokinase combination antiplatelet agents anticoagulants cause bleeding complications\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Nalidixic acid, Nalidixic acid \t melphalan, melphalan \n",
      "Sentences: \n",
      "\tDRUG INTERACTIONS There are no known drug / drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high - dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . \n",
      "\t DRUG INTERACTIONS known drug drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid high dose intravenous melphalan caused deaths children haemorrhagic enterocolitis\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t cimetidine, cimetidine \t mebendazole, mebendazole \n",
      "Sentences: \n",
      "\tPreliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole . \n",
      "\t Preliminary evidence suggests cimetidine inhibits mebendazole metabolism result increase plasma concentrations mebendazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t mebendazole, mebendazole \t mebendazole, mebendazole \n",
      "Sentences: \n",
      "\tPreliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole . \n",
      "\t Preliminary evidence suggests cimetidine inhibits mebendazole metabolism result increase plasma concentrations mebendazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t beta adrenergic aerosol bronchodilators, beta adrenergic aerosol bronchodilators \t Alupent, Alupent \n",
      "Sentences: \n",
      "\tOther beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent ( metaproterenol sulfate USP ) because they may have additive effects . \n",
      "\t beta adrenergic aerosol bronchodilators concomitantly Alupent metaproterenol sulfate USP additive effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t beta adrenergic aerosol bronchodilators, beta adrenergic aerosol bronchodilators \t metaproterenol sulfate, metaproterenol sulfate \n",
      "Sentences: \n",
      "\tOther beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent ( metaproterenol sulfate USP ) because they may have additive effects . \n",
      "\t beta adrenergic aerosol bronchodilators concomitantly Alupent metaproterenol sulfate USP additive effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t Beta adrenergic agonists, Beta adrenergic agonists \t tricyclic antidepressants, tricyclic antidepressants \n",
      "Sentences: \n",
      "\tBeta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . \n",
      "\t Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants action beta adrenergic agonists vascular system potentiated\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t tricyclic antidepressants, tricyclic antidepressants \t beta adrenergic agonists, beta adrenergic agonists \n",
      "Sentences: \n",
      "\tBeta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . \n",
      "\t Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants action beta adrenergic agonists vascular system potentiated\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t XENICAL, XENICAL \t alcohol, alcohol \n",
      "Sentences: \n",
      "\tAlcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . \n",
      "\t Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t XENICAL, XENICAL \t contraceptives, contraceptives \n",
      "Sentences: \n",
      "\tOral Contraceptives : In 20 normal - weight female subjects , the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation - suppressing action of oral contraceptives . \n",
      "\t Oral Contraceptives NUMBER normal weight female subjects treatment XENICAL NUMBER mg times day NUMBER days resulted changes ovulation suppressing action oral contraceptives\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Trilostane, Trilostane \t aminoglutethimide, aminoglutethimide \n",
      "Sentences: \n",
      "\tTrilostane may interact with aminoglutethimide or mitotane ( causing too great a decrease in adrenal function ) . \n",
      "\t Trilostane interact aminoglutethimide mitotane causing great decrease adrenal function\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t paclitaxel, paclitaxel \t HERCEPTIN, HERCEPTIN \n",
      "Sentences: \n",
      "\tAdministration of paclitaxel in combination with HERCEPTIN resulted in a two - fold decrease in HERCEPTIN clearance in a non - human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . \n",
      "\t Administration paclitaxel combination HERCEPTIN resulted fold decrease HERCEPTIN clearance non human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t HERCEPTIN, HERCEPTIN \t HERCEPTIN, HERCEPTIN \n",
      "Sentences: \n",
      "\tAdministration of paclitaxel in combination with HERCEPTIN resulted in a two - fold decrease in HERCEPTIN clearance in a non - human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . \n",
      "\t Administration paclitaxel combination HERCEPTIN resulted fold decrease HERCEPTIN clearance non human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ZAVESCA, ZAVESCA \t Cerezyme, Cerezyme \n",
      "Sentences: \n",
      "\tWhile co - administration of ZAVESCA appeared to increase the clearance of Cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme . \n",
      "\t co administration ZAVESCA appeared increase clearance Cerezyme NUMBER results conclusive small number subjects studied patients took variable doses Cerezyme\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Cerezyme, Cerezyme \t imiglucerase, imiglucerase \n",
      "Sentences: \n",
      "\tCombination therapy with Cerezyme ( imiglucerase ) and ZAVESCA is not indicated . \n",
      "\t Combination therapy Cerezyme imiglucerase ZAVESCA indicated\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, advise \n",
      "Entities: \t CYLERT, CYLERT \t antiepileptic medications, antiepileptic medications \n",
      "Sentences: \n",
      "\tDecreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications . \n",
      "\t Decreased seizure threshold reported patients receiving CYLERT concomitantly antiepileptic medications\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Digoxin, Digoxin \t digoxin, digoxin \n",
      "Sentences: \n",
      "\tDigoxin : There was a slight increase in the area under the curve ( AUC , 11 % ) and mean peak drug concentration ( Cmax , 18 % ) of digoxin with the co - administration of 100 mg sitagliptin for 10 days . \n",
      "\t Digoxin slight increase area curve AUC NUMBER mean peak drug concentration Cmax NUMBER digoxin co administration NUMBER mg sitagliptin NUMBER days\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Digoxin, Digoxin \t sitagliptin, sitagliptin \n",
      "Sentences: \n",
      "\tDigoxin : There was a slight increase in the area under the curve ( AUC , 11 % ) and mean peak drug concentration ( Cmax , 18 % ) of digoxin with the co - administration of 100 mg sitagliptin for 10 days . \n",
      "\t Digoxin slight increase area curve AUC NUMBER mean peak drug concentration Cmax NUMBER digoxin co administration NUMBER mg sitagliptin NUMBER days\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t digoxin, digoxin \t JANUVIA, JANUVIA \n",
      "Sentences: \n",
      "\tNo dosage adjustment of digoxin or JANUVIA is recommended . \n",
      "\t dosage adjustment digoxin JANUVIA recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t rocuronium bromide, rocuronium bromide \t succinylcholine, succinylcholine \n",
      "Sentences: \n",
      "\tDrug Interactions : The use of ZEMURON ( rocuronium bromide ) Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . \n",
      "\t Drug Interactions use ZEMURON rocuronium bromide Injection succinylcholine purpose attenuating effects succinylcholine studied\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ZEMURON, ZEMURON \t succinylcholine, succinylcholine \n",
      "Sentences: \n",
      "\tThe median duration of action of ZEMURON 0.6 mg / kg administered after a 1 mg / kg dose of succinylcholine when T 1 returned to 75 % of control was 36 minutes ( range 14 - 57 , n=12 ) vs. \n",
      "\t median duration action ZEMURON NUMBER mg kg administered NUMBER mg kg dose succinylcholine T NUMBER returned NUMBER control NUMBER minutes range NUMBER NUMBER n=12 vs.\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t alcohol, alcohol \t methyprylon, methyprylon \n",
      "Sentences: \n",
      "\tConcurrent use of alcohol and other CNS depression - producing drugs may increase the CNS depressant effects of methyprylon or these other medications . \n",
      "\t Concurrent use alcohol CNS depression producing drugs increase CNS depressant effects methyprylon medications\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t FELDENE, FELDENE \t aspirin, aspirin \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t Plasma levels piroxicam depressed approximately NUMBER normal values FELDENE administered conjunction aspirin NUMBER mg day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti inflammatory agents including FELDENE reported increase steady state plasma lithium levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t antacids, antacids \t piroxicam, piroxicam \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t Plasma levels piroxicam depressed approximately NUMBER normal values FELDENE administered conjunction aspirin NUMBER mg day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti inflammatory agents including FELDENE reported increase steady state plasma lithium levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t aspirin, aspirin \t meloxicam, meloxicam \n",
      "Sentences: \n",
      "\tAspirin : Concomitant administration of aspirin ( 1000 mg TID ) to healthy volunteers tended to increase the AUC ( 10 % ) and Cmax ( 24 % ) of meloxicam . \n",
      "\t Aspirin Concomitant administration aspirin NUMBER mg TID healthy volunteers tended increase AUC NUMBER Cmax NUMBER meloxicam\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t NSAIDs, NSAIDs \t aspirin, aspirin \n",
      "Sentences: \n",
      "\thowever , as with other NSAIDs , concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects . \n",
      "\t NSAIDs concomitant administration meloxicam aspirin generally recommended potential increased adverse effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t methotrexate, methotrexate \t meloxicam, meloxicam \n",
      "Sentences: \n",
      "\tIn vitro , methotrexate did not displace meloxicam from its human serum binding sites . \n",
      "\t vitro methotrexate displace meloxicam human serum binding sites\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t warfarin, warfarin \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tThe effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR ( International Normalized Ratio ) between 1.2 and 1.8 . \n",
      "\t effect meloxicam anticoagulant effect warfarin studied group healthy subjects receiving daily doses warfarin produced INR International Normalized Ratio NUMBER NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Alcohol, Alcohol \t alcohol, alcohol \n",
      "Sentences: \n",
      "\tUsage with Alcohol : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine . \n",
      "\t Usage Alcohol potential increased CNS depressants effects alcohol caution patients currently receiving pentazocine\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t digoxin, digoxin \t metoclopramide, metoclopramide \n",
      "Sentences: \n",
      "\tAbsorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) . \n",
      "\t Absorption drugs stomach diminished e.g. digoxin metoclopramide rate and/or extent absorption drugs small bowel increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t paricalcitol, paricalcitol \t paricalcitol, paricalcitol \n",
      "Sentences: \n",
      "\tA multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . \n",
      "\t multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0- paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t paricalcitol, paricalcitol \t ketoconazole, ketoconazole \n",
      "Sentences: \n",
      "\tA multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . \n",
      "\t multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0- paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Probenecid, Probenecid \t riboflavin, riboflavin \n",
      "Sentences: \n",
      "\tProbenecid - concurrent use decreases gastrointestinal absorption of riboflavin ; \n",
      "\t Probenecid concurrent use decreases gastrointestinal absorption riboflavin\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t riboflavin, riboflavin \t probenecid, probenecid \n",
      "Sentences: \n",
      "\trequirements for riboflavin may be increased in patients receiving probenecid . \n",
      "\t requirements riboflavin increased patients receiving probenecid\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t steroids, steroids \t ACTH, ACTH \n",
      "Sentences: \n",
      "\tHypokalemia may develop during concomitant use of steroids or ACTH . \n",
      "\t Hypokalemia develop concomitant use steroids ACTH\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t cholestyramine, cholestyramine \t ezetimibe, ezetimibe \n",
      "Sentences: \n",
      "\tCholestyramine : Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55 % . \n",
      "\t Cholestyramine Concomitant cholestyramine administration decreased mean AUC total ezetimibe approximately NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t tranylcypromine, tranylcypromine \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t selegiline, selegiline \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t furazolidone, furazolidone \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t quinidine, quinidine \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t amantadine, amantadine \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t diphenhydramine, diphenhydramine \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t anticholinergics, anticholinergics \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t potassium chloride, potassium chloride \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t antacids, antacids \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t absorbent - type anti - diarrhea medicines, absorbent type anti diarrhea medicines \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t phenothiazines, phenothiazines \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, Methscopolamine \t chlorpromazine, chlorpromazine \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Sulfamethizole, Sulfamethizole \t barbiturates, barbiturates \n",
      "Sentences: \n",
      "\tSulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . \n",
      "\t Sulfamethizole increase effects barbiturates tolbutamide uricosurics\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Sulfamethizole, Sulfamethizole \t tolbutamide, tolbutamide \n",
      "Sentences: \n",
      "\tSulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . \n",
      "\t Sulfamethizole increase effects barbiturates tolbutamide uricosurics\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Sulfamethizole, Sulfamethizole \t uricosurics, uricosurics \n",
      "Sentences: \n",
      "\tSulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . \n",
      "\t Sulfamethizole increase effects barbiturates tolbutamide uricosurics\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfonylurea agents, sulfonylurea agents \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tIt may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . \n",
      "\t interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Vindesine, Vindesine \t vaccine, vaccine \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines potentiate replication vaccine virus increase effects vaccination decrease patient 's response vaccine Mitomycin C cause shortness breath bronchospasm Killed virus vaccines decrease patient 's response vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Vindesine, Vindesine \t vaccine, vaccine \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines potentiate replication vaccine virus increase effects vaccination decrease patient 's response vaccine Mitomycin C cause shortness breath bronchospasm Killed virus vaccines decrease patient 's response vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Live virus vaccines, Live virus vaccines \t vaccine, vaccine \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines potentiate replication vaccine virus increase effects vaccination decrease patient 's response vaccine Mitomycin C cause shortness breath bronchospasm Killed virus vaccines decrease patient 's response vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Live virus vaccines, Live virus vaccines \t Mitomycin - C, Mitomycin C \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines potentiate replication vaccine virus increase effects vaccination decrease patient 's response vaccine Mitomycin C cause shortness breath bronchospasm Killed virus vaccines decrease patient 's response vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t anticonvulsants, anticonvulsants \t mifepristone, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort certain anticonvulsants phenytoin phenobarbital carbamazepine induce mifepristone metabolism lowering serum levels mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, phenytoin \t mifepristone, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort certain anticonvulsants phenytoin phenobarbital carbamazepine induce mifepristone metabolism lowering serum levels mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenobarbital, phenobarbital \t mifepristone, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort certain anticonvulsants phenytoin phenobarbital carbamazepine induce mifepristone metabolism lowering serum levels mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t carbamazepine, carbamazepine \t mifepristone, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort certain anticonvulsants phenytoin phenobarbital carbamazepine induce mifepristone metabolism lowering serum levels mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t thiabendazole, thiabendazole \t xanthine derivatives, xanthine derivatives \n",
      "Sentences: \n",
      "\tTherefore , when concomitant use of thiabendazole and xanthine derivatives is anticipated , it may be necessary to monitor blood levels and/or reduce the dosage of such compounds . \n",
      "\t concomitant use thiabendazole xanthine derivatives anticipated necessary monitor blood levels and/or reduce dosage compounds\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t mirtazapine, mirtazapine \t mirtazapine, mirtazapine \n",
      "Sentences: \n",
      "\tWhile in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied . \n",
      "\t vitro studies shown mirtazapine potent inhibitor enzymes indication mirtazapine likely clinically significant inhibitory effect metabolism drugs substrates cytochrome P450 enzymes concomitant use REMERON SolTab drugs metabolized enzymes formally studied\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t alcohol, alcohol \t mirtazapine, mirtazapine \n",
      "Sentences: \n",
      "\tAlcohol : Concomitant administration of alcohol ( equivalent to 60 g ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 6 healthy male subjects . \n",
      "\t Alcohol Concomitant administration alcohol equivalent NUMBER g minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy male subjects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t alcohol, alcohol \t Diazepam, Diazepam \n",
      "Sentences: \n",
      "\tAccordingly , patients should be advised to avoid alcohol while taking REMERON SolTab . Diazepam : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . \n",
      "\t Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Potassium - Sparing Diuretics, Potassium Sparing Diuretics \t ACEON, ACEON \n",
      "Sentences: \n",
      "\tPotassium Supplements and Potassium - Sparing Diuretics : ACEON Tablets may increase serum potassium because of its potential to decrease aldosterone production . \n",
      "\t Potassium Supplements Potassium Sparing Diuretics ACEON Tablets increase serum potassium potential decrease aldosterone production\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium - sparing diuretics, potassium sparing diuretics \t cyclosporine, cyclosporine \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use potassium sparing diuretics spironolactone amiloride triamterene potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine increase risk hyperkalemia\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t amiloride, amiloride \t cyclosporine, cyclosporine \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use potassium sparing diuretics spironolactone amiloride triamterene potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine increase risk hyperkalemia\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t triamterene, triamterene \t cyclosporine, cyclosporine \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use potassium sparing diuretics spironolactone amiloride triamterene potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine increase risk hyperkalemia\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium, potassium \t cyclosporine, cyclosporine \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use potassium sparing diuretics spironolactone amiloride triamterene potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine increase risk hyperkalemia\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t indomethacin, indomethacin \t cyclosporine, cyclosporine \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use potassium sparing diuretics spironolactone amiloride triamterene potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine increase risk hyperkalemia\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Gentamicin, Gentamicin \t gentamicin, gentamicin \n",
      "Sentences: \n",
      "\tGentamicin : Animal data have suggested the possibility of interaction between perindopril and gentamicin . \n",
      "\t Gentamicin Animal data suggested possibility interaction perindopril gentamicin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ACEON, ACEON \t perindopril, perindopril \n",
      "Sentences: \n",
      "\tFood Interaction : Oral administration of ACEON Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state . \n",
      "\t Food Interaction Oral administration ACEON Tablets food significantly lower rate extent perindopril absorption relative fasted state\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t pentazocine, pentazocine \t opioid agonist analgesic, opioid agonist analgesic \n",
      "Sentences: \n",
      "\tInteraction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . \n",
      "\t Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol buprenorphine administered patients received receiving course therapy proof opioid agonist analgesic\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t nalbuphine, nalbuphine \t opioid agonist analgesic, opioid agonist analgesic \n",
      "Sentences: \n",
      "\tInteraction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . \n",
      "\t Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol buprenorphine administered patients received receiving course therapy proof opioid agonist analgesic\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t Dopamine antagonists, Dopamine antagonists \t Permax, Permax \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t neuroleptics, neuroleptics \t Permax, Permax \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t phenothiazines, phenothiazines \t Permax, Permax \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t butyrophenones, butyrophenones \t Permax, Permax \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t metoclopramide, metoclopramide \t dopamine agonist, dopamine agonist \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t MYCAMINE, MYCAMINE \t sirolimus, sirolimus \n",
      "Sentences: \n",
      "\tSirolimus AUC was increased by 21 % with no effect on Cmax in the presence of steady - state MYCAMINE compared with sirolimus alone . \n",
      "\t Sirolimus AUC increased NUMBER effect Cmax presence steady state MYCAMINE compared sirolimus\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t MYCAMINE, MYCAMINE \t nifedipine, nifedipine \n",
      "Sentences: \n",
      "\tNifedipine AUC and Cmax were increased by 18 % and 42 % , respectively , in the presence of steady - state MYCAMINE compared with nifedipine alone . \n",
      "\t Nifedipine AUC Cmax increased NUMBER NUMBER respectively presence steady state MYCAMINE compared nifedipine\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t sirolimus, sirolimus \t MYCAMINE, MYCAMINE \n",
      "Sentences: \n",
      "\tPatients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . \n",
      "\t Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t nifedipine, nifedipine \t MYCAMINE, MYCAMINE \n",
      "Sentences: \n",
      "\tPatients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . \n",
      "\t Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t anticholinergic drugs, anticholinergic drugs \t triprolidine, triprolidine \n",
      "Sentences: \n",
      "\tThe effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . \n",
      "\t effects anticholinergic drugs atropine tricyclic antidepressants enhanced concomitant administration triprolidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t atropine, atropine \t triprolidine, triprolidine \n",
      "Sentences: \n",
      "\tThe effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . \n",
      "\t effects anticholinergic drugs atropine tricyclic antidepressants enhanced concomitant administration triprolidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t streptozocin, streptozocin \t phenytoin, phenytoin \n",
      "Sentences: \n",
      "\tThe concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity . \n",
      "\t concurrent use streptozocin phenytoin reported case result reduced streptozocin cytotoxicity\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t phenytoin, phenytoin \t streptozocin, streptozocin \n",
      "Sentences: \n",
      "\tThe concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity . \n",
      "\t concurrent use streptozocin phenytoin reported case result reduced streptozocin cytotoxicity\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t MAO inhibitors, MAO inhibitors \t pseudoephedrine, pseudoephedrine \n",
      "Sentences: \n",
      "\tMAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine . \n",
      "\t MAO inhibitors beta adrenergic blockers increase effects pseudoephedrine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t aminoglycoside, aminoglycoside \t antibiotic, antibiotic \n",
      "Sentences: \n",
      "\tSome diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue . \n",
      "\t diuretics enhance aminoglycoside toxicity altering antibiotic concentrations serum tissue\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t vasoconstrictor agents, vasoconstrictor agents \t nicotine, nicotine \n",
      "Sentences: \n",
      "\tConcurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . \n",
      "\t Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking result enhanced vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sumatriptan, sumatriptan \t nicotine, nicotine \n",
      "Sentences: \n",
      "\tConcurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . \n",
      "\t Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking result enhanced vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t fluconazole, fluconazole \t midazolam, midazolam \n",
      "Sentences: \n",
      "\tDrugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . \n",
      "\t Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t rifampin, rifampin \t carbamazepine, carbamazepine \n",
      "Sentences: \n",
      "\tInducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . \n",
      "\t Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t rifampin, rifampin \t phenytoin, phenytoin \n",
      "Sentences: \n",
      "\tInducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . \n",
      "\t Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t carbamazepine, carbamazepine \t phenytoin, phenytoin \n",
      "Sentences: \n",
      "\tInducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . \n",
      "\t Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, phenytoin \t midazolam, midazolam \n",
      "Sentences: \n",
      "\tInducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . \n",
      "\t Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, VERSED Syrup \t fentanyl, fentanyl \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, VERSED Syrup \t droperidol, droperidol \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, advise \n",
      "Entities: \t Salicylates, Salicylates \t anticoagulant drugs, anticoagulant drugs \n",
      "Sentences: \n",
      "\tSalicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding . \n",
      "\t Salicylates given concomitantly anticoagulant drugs predispose systemic bleeding\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t penicillin, penicillin \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t thiopental, thiopental \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t thyroxine, thyroxine \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t triiodothyronine, triiodothyronine \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t phenytoin, phenytoin \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t sulfinpyrazone, sulfinpyrazone \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t naproxen, naproxen \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t methotrexate, methotrexate \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Salicylate, Salicylate \t corticosteroids, corticosteroids \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t oxandrolone, oxandrolone \t R - warfarin, R warfarin \n",
      "Sentences: \n",
      "\tWarfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S - warfarin half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr / mL : similar increases in R - warfarin half - life and AUC were also detected . \n",
      "\t Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase S warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng*hr mL similar increases R warfarin half life AUC detected\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Adrenal steroids, Adrenal steroids \t ACTH, ACTH \n",
      "Sentences: \n",
      "\tAdrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . \n",
      "\t Adrenal steroids ACTH patients edema concomitant administration adrenal cortical steroids ACTH increase edema\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t warfarin, warfarin \t Exelon, Exelon \n",
      "Sentences: \n",
      "\tThe elevation of prothrombin time induced by warfarin is not affected by administration of Exelon . \n",
      "\t elevation prothrombin time induced warfarin affected administration Exelon\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Exelon, Exelon \t rivastigmine, rivastigmine \n",
      "Sentences: \n",
      "\tEffect of Other Drugs on the Metabolism of Exelon : Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine . \n",
      "\t Effect Drugs Metabolism Exelon Drugs induce inhibit CYP450 metabolism expected alter metabolism rivastigmine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Anticholinergics, Anticholinergics \t anticholinergic medications, anticholinergic medications \n",
      "Sentences: \n",
      "\tUse with Anticholinergics : Because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications . \n",
      "\t Use Anticholinergics mechanism action cholinesterase inhibitors potential interfere activity anticholinergic medications\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Cholinomimetics, Cholinomimetics \t Cholinesterase Inhibitors, Cholinesterase Inhibitors \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use Cholinomimetics Cholinesterase Inhibitors synergistic effect expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Cholinomimetics, Cholinomimetics \t cholinesterase inhibitors, cholinesterase inhibitors \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use Cholinomimetics Cholinesterase Inhibitors synergistic effect expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Cholinesterase Inhibitors, Cholinesterase Inhibitors \t bethanechol, bethanechol \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use Cholinomimetics Cholinesterase Inhibitors synergistic effect expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t cholinesterase inhibitors, cholinesterase inhibitors \t succinylcholine, succinylcholine \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use Cholinomimetics Cholinesterase Inhibitors synergistic effect expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t TRENTAL, TRENTAL \t theophylline, theophylline \n",
      "Sentences: \n",
      "\tConcomitant administration of TRENTAL and theophylline -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . \n",
      "\t Concomitant administration TRENTAL theophylline -containing drugs leads increased theophylline levels theophylline toxicity individuals\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t diuretics, diuretics \t antiarrhythmics, antiarrhythmics \n",
      "Sentences: \n",
      "\tTRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . \n",
      "\t TRENTAL concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics observed problems\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t methyldopa, methyldopa \t antihypertensive drugs, antihypertensive drugs \n",
      "Sentences: \n",
      "\tWhen methyldopa is used with other antihypertensive drugs , potentiation of antihypertensive effect may occur . \n",
      "\t methyldopa antihypertensive drugs potentiation antihypertensive effect occur\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t methyldopa, methyldopa \t ferrous sulfate, ferrous sulfate \n",
      "Sentences: \n",
      "\tSeveral studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate . \n",
      "\t studies demonstrate decrease bioavailability methyldopa ingested ferrous sulfate ferrous gluconate\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t methyldopa, methyldopa \t ferrous gluconate, ferrous gluconate \n",
      "Sentences: \n",
      "\tSeveral studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate . \n",
      "\t studies demonstrate decrease bioavailability methyldopa ingested ferrous sulfate ferrous gluconate\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t methyldopa, methyldopa \t ferrous sulfate, ferrous sulfate \n",
      "Sentences: \n",
      "\tCoadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended . \n",
      "\t Coadministration methyldopa ferrous sulfate ferrous gluconate recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t methyldopa, methyldopa \t ferrous gluconate, ferrous gluconate \n",
      "Sentences: \n",
      "\tCoadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended . \n",
      "\t Coadministration methyldopa ferrous sulfate ferrous gluconate recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Methyldopa, Methyldopa \t vanillylmandelic acid, vanillylmandelic acid \n",
      "Sentences: \n",
      "\tMethyldopa does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to vanillin . \n",
      "\t Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t VMA, VMA \t vanillylmandelic acid, vanillylmandelic acid \n",
      "Sentences: \n",
      "\tMethyldopa does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to vanillin . \n",
      "\t Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t mycophenolate mofetil, mycophenolate mofetil \t azathioprine, azathioprine \n",
      "Sentences: \n",
      "\tAzathioprine / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . \n",
      "\t Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t Myfortic, Myfortic \t cholestyramine, cholestyramine \n",
      "Sentences: \n",
      "\tTherefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . \n",
      "\t administer Myfortic cholestyramine agents interfere enterohepatic recirculation drugs bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t activated charcoal, activated charcoal \t Myfortic, Myfortic \n",
      "Sentences: \n",
      "\tTherefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . \n",
      "\t administer Myfortic cholestyramine agents interfere enterohepatic recirculation drugs bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Contraceptives, Contraceptives \t Myfortic, Myfortic \n",
      "Sentences: \n",
      "\tOral Contraceptives : Given the different metabolism of Myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected . \n",
      "\t Oral Contraceptives Given different metabolism Myfortic oral contraceptives drug interaction classes drug expected\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Live Vaccines, Live Vaccines \t live attenuated vaccines, live attenuated vaccines \n",
      "Sentences: \n",
      "\tLive Vaccines : During treatment with Myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . \n",
      "\t Live Vaccines treatment Myfortic use live attenuated vaccines avoided patients advised vaccinations effective\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t antibiotics, antibiotics \t ganglion blockers, ganglion blockers \n",
      "Sentences: \n",
      "\tPatients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers . \n",
      "\t Patients receiving antibiotics sulfonamides generally treated ganglion blockers\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t sulfonamides, sulfonamides \t ganglion blockers, ganglion blockers \n",
      "Sentences: \n",
      "\tPatients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers . \n",
      "\t Patients receiving antibiotics sulfonamides generally treated ganglion blockers\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Melatonin, Melatonin \t NSAIDs, NSAIDs \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t Melatonin interact following drugs aspirin NSAIDs lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids interfere efficacy corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t melatonin, melatonin \t progestin, progestin \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t Melatonin interact following drugs aspirin NSAIDs lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids interfere efficacy corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t melatonin, melatonin \t corticosteroids, corticosteroids \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t Melatonin interact following drugs aspirin NSAIDs lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids interfere efficacy corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t tramadol, tramadol \t Ultram, Ultram \n",
      "Sentences: \n",
      "\tCombination with tramadol ( Ultram ) is associated with increased risk of seizures . \n",
      "\t Combination tramadol Ultram associated increased risk seizures\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Caffeine, Caffeine \t levomepromazine, levomepromazine \n",
      "Sentences: \n",
      "\tCaffeine and/or stimulantes of the ephedrine / amphetamine type may counteract the specific actions of levomepromazine . \n",
      "\t Caffeine and/or stimulantes ephedrine amphetamine type counteract specific actions levomepromazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Guanethidine, Guanethidine \t minoxidil, minoxidil \n",
      "Sentences: \n",
      "\tInteraction with Guanethidine : Although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects . \n",
      "\t Interaction Guanethidine minoxidil cause orthostatic hypotension administration patients receiving guanethidine result profound orthostatic effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Guanethidine, Guanethidine \t guanethidine, guanethidine \n",
      "Sentences: \n",
      "\tInteraction with Guanethidine : Although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects . \n",
      "\t Interaction Guanethidine minoxidil cause orthostatic hypotension administration patients receiving guanethidine result profound orthostatic effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Phenobarbital, Phenobarbital \t montelukast, montelukast \n",
      "Sentences: \n",
      "\tPhenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . \n",
      "\t Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER following single 10-mg dose montelukast\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Phenobarbital, Phenobarbital \t montelukast, montelukast \n",
      "Sentences: \n",
      "\tPhenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . \n",
      "\t Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER following single 10-mg dose montelukast\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t prazosin, prazosin \t terazosin, terazosin \n",
      "Sentences: \n",
      "\tProAmatine . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . \n",
      "\t ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible supporting experimental evidence high renal clearance desglymidodrine base active tubular secretion base secreting system responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t prazosin, prazosin \t doxazosin, doxazosin \n",
      "Sentences: \n",
      "\tProAmatine . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . \n",
      "\t ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible supporting experimental evidence high renal clearance desglymidodrine base active tubular secretion base secreting system responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t barbiturates, barbiturates \t reserpine, reserpine \n",
      "Sentences: \n",
      "\tThalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . \n",
      "\t Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t roxithromycin, roxithromycin \t astemizole, astemizole \n",
      "Sentences: \n",
      "\tAlthough such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended . \n",
      "\t reaction demonstrated roxithromycin concomitant administration roxithromycin terfenadine astemizole recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t roxithromycin, roxithromycin \t roxithromycin, roxithromycin \n",
      "Sentences: \n",
      "\tAlthough such a risk is not verified for roxithromycin , combination of roxithromycin with such drugs is not recommended . \n",
      "\t risk verified roxithromycin combination roxithromycin drugs recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t ketoconazole, ketoconazole \t terfenadine, terfenadine \n",
      "Sentences: \n",
      "\tKetoconazole : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events , e.g. \n",
      "\t Ketoconazole Spontaneous adverse reaction reports patients taking concomitant ketoconazole recommended doses terfenadine demonstrate QT interval prolongation rare cardiac events e.g.\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t metronidazole, metronidazole \t terfenadine, terfenadine \n",
      "Sentences: \n",
      "\tDue to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . \n",
      "\t chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending examination potential interactions\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t terfenadine, terfenadine \t azithromycin, azithromycin \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t troleandomycin, troleandomycin \t macrolide antibiotics, macrolide antibiotics \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t troleandomycin, troleandomycin \t azithromycin, azithromycin \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t terfenadine, terfenadine \t macrolide antibiotics, macrolide antibiotics \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t UNIVASC, UNIVASC \t moexpril, moexpril \n",
      "Sentences: \n",
      "\tThe possibility of hypotensive effects with UNIVASC can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC . If this is not possible , the starting dose of moexpril should be reduced .. \n",
      "\t possibility hypotensive effects UNIVASC minimized discontinuing diuretic therapy days cautiously increasing salt intake initiation treatment UNIVASC possible starting dose moexpril reduced\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Potassium - Sparing Diuretics, Potassium Sparing Diuretics \t UNIVASC, UNIVASC \n",
      "Sentences: \n",
      "\tPotassium Supplements and Potassium - Sparing Diuretics : UNIVASC can increase serum potassium because it decreases aldosterone secretion . \n",
      "\t Potassium Supplements Potassium Sparing Diuretics UNIVASC increase serum potassium decreases aldosterone secretion\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t antimycotic agents, antimycotic agents \t miconazole, miconazole \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t miconazole, miconazole \t clarithromycin, clarithromycin \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t macrolide antibiotics, macrolide antibiotics \t clarithromycin, clarithromycin \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t macrolide antibiotics, macrolide antibiotics \t oxybutynin, oxybutynin \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t erythromycin, erythromycin \t oxybutynin, oxybutynin \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t clarithromycin, clarithromycin \t oxybutynin, oxybutynin \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t antacid, antacid \t aluminum hydroxide, aluminum hydroxide \n",
      "Sentences: \n",
      "\tConcurrent ingestion of antacid ( 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . \n",
      "\t Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Sulfoxone, Sulfoxone \t barbiturates, barbiturates \n",
      "Sentences: \n",
      "\tSulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . \n",
      "\t Sulfoxone increase effects barbiturates tolbutamide uricosurics\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Sulfoxone, Sulfoxone \t tolbutamide, tolbutamide \n",
      "Sentences: \n",
      "\tSulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . \n",
      "\t Sulfoxone increase effects barbiturates tolbutamide uricosurics\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Sulfoxone, Sulfoxone \t uricosurics, uricosurics \n",
      "Sentences: \n",
      "\tSulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . \n",
      "\t Sulfoxone increase effects barbiturates tolbutamide uricosurics\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfonylurea agents, sulfonylurea agents \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tIt may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . \n",
      "\t interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfonylureas, sulfonylureas \t insulin, insulin \n",
      "Sentences: \n",
      "\tIn adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . \n",
      "\t adult diabetic patients treatment sulfonylureas insulin change clinical effects TOLECTIN hypoglycemic agents\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfonylureas, sulfonylureas \t TOLECTIN, TOLECTIN \n",
      "Sentences: \n",
      "\tIn adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . \n",
      "\t adult diabetic patients treatment sulfonylureas insulin change clinical effects TOLECTIN hypoglycemic agents\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfonylureas, sulfonylureas \t hypoglycemic agents, hypoglycemic agents \n",
      "Sentences: \n",
      "\tIn adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . \n",
      "\t adult diabetic patients treatment sulfonylureas insulin change clinical effects TOLECTIN hypoglycemic agents\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t insulin, insulin \t hypoglycemic, hypoglycemic \n",
      "Sentences: \n",
      "\tAcromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT . \n",
      "\t Acromegalic patients diabetes mellitus treated insulin and/or oral hypoglycemic agents require dose reductions therapeutic agents initiation therapy SOMAVERT\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t short - acting beta adrenergic aerosol bronchodilators, short acting beta adrenergic aerosol bronchodilators \t MAXAIR AUTOHALER, MAXAIR AUTOHALER \n",
      "Sentences: \n",
      "\tOther short - acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects . \n",
      "\t short acting beta adrenergic aerosol bronchodilators concomitantly MAXAIR AUTOHALER additive effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Probenecid, Probenecid \t pramipexole, pramipexole \n",
      "Sentences: \n",
      "\tProbenecid : Probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics ( N= 12 ) . \n",
      "\t Probenecid Probenecid known inhibitor renal tubular secretion organic acids aruonic transporter noticeably influence pramipexole pharmacokinetics N= NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t cimetidine, cimetidine \t pramipexole, pramipexole \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t drugs eliminated renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t ranitidine, ranitidine \t pramipexole, pramipexole \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t drugs eliminated renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t vitamin K antagonists, vitamin K antagonists \t TNKase, TNKase \n",
      "Sentences: \n",
      "\tAnticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . \n",
      "\t Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors increase risk bleeding administered prior TNKase therapy\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t proton pump inhibitors, proton pump inhibitors \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tPatients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time . \n",
      "\t Patients treated proton pump inhibitors warfarin concomitantly monitored increases INR prothrombin time\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t tetrahydrocannabinol, tetrahydrocannabinol \t pantoprazole, pantoprazole \n",
      "Sentences: \n",
      "\tLaboratory Tests There have been reports of false - positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving most proton pump inhibitors , including pantoprazole . \n",
      "\t Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t THC, THC \t proton pump inhibitors, proton pump inhibitors \n",
      "Sentences: \n",
      "\tLaboratory Tests There have been reports of false - positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving most proton pump inhibitors , including pantoprazole . \n",
      "\t Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t THC, THC \t pantoprazole, pantoprazole \n",
      "Sentences: \n",
      "\tLaboratory Tests There have been reports of false - positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving most proton pump inhibitors , including pantoprazole . \n",
      "\t Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Rifampicin, Rifampicin \t phenytoin, phenytoin \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Rifampicin, Rifampicin \t ondansetron, ondansetron \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, phenytoin \t ondansetron, ondansetron \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t carbamazepine, carbamazepine \t ondansetron, ondansetron \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t CNS depressants, CNS depressants \t hypnotics, hypnotics \n",
      "Sentences: \n",
      "\tThe concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . \n",
      "\t concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol produce additive CNS depressant effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t CNS depressants, CNS depressants \t tranquilizers, tranquilizers \n",
      "Sentences: \n",
      "\tThe concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . \n",
      "\t concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol produce additive CNS depressant effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t CNS depressants, CNS depressants \t anesthetics, anesthetics \n",
      "Sentences: \n",
      "\tThe concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . \n",
      "\t concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol produce additive CNS depressant effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t CNS depressants, CNS depressants \t phenothiazines, phenothiazines \n",
      "Sentences: \n",
      "\tThe concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . \n",
      "\t concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol produce additive CNS depressant effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Imexon, Imexon \t dacarbazine, dacarbazine \n",
      "Sentences: \n",
      "\tImexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells . \n",
      "\t Imexon dacarbazine additive effects vitro vivo human A375 melanoma cells\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Warfarin, Warfarin \t citalopram, citalopram \n",
      "Sentences: \n",
      "\tWarfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , fluoxetine ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , paroxetine ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , amitriptyline ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) . \n",
      "\t Warfarin users increased odds ratio gastrointestinal bleeding initiation citalopram = NUMBER NUMBER CI NUMBER NUMBER fluoxetine = NUMBER NUMBER CI NUMBER NUMBER paroxetine = NUMBER NUMBER CI NUMBER NUMBER amitriptyline = NUMBER NUMBER CI NUMBER NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t citalopram, citalopram \t mirtazapine, mirtazapine \n",
      "Sentences: \n",
      "\tWarfarin users who initiated citalopram , fluoxetine , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding . \n",
      "\t Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t dexmedetomidine, dexmedetomidine \t analgesic, analgesic \n",
      "Sentences: \n",
      "\tWe concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an analgesic in humans . \n",
      "\t concluded combined administration dexmedetomidine ephedrine beneficial effects treatment pain causing sedation limits use dexmedetomidine analgesic humans\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t amphetamine, amphetamine \t quinpirole, quinpirole \n",
      "Sentences: \n",
      "\tIn female rats , neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole -free controls sensitized to amphetamine . \n",
      "\t female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared quinpirole -free controls sensitized amphetamine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t amphetamine, amphetamine \t quinpirole, quinpirole \n",
      "Sentences: \n",
      "\tMale rats demonstrated sensitization to amphetamine , although this was muted compared with female rats , and were unaffected by neonatal quinpirole . \n",
      "\t Male rats demonstrated sensitization amphetamine muted compared female rats unaffected neonatal quinpirole\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, quinpirole \t amphetamine, amphetamine \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t Rats treated neonatal quinpirole enhanced time spent amphetamine -paired context compared quinpirole -free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, quinpirole \t amphetamine, amphetamine \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t Rats treated neonatal quinpirole enhanced time spent amphetamine -paired context compared quinpirole -free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, quinpirole \t amphetamine, amphetamine \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t Rats treated neonatal quinpirole enhanced time spent amphetamine -paired context compared quinpirole -free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Moxifloxacin, Moxifloxacin \t sucralfate, sucralfate \n",
      "Sentences: \n",
      "\tMoxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi - minerals in neutral media . \n",
      "\t Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media erythromycin basic media multi minerals neutral media\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Lomefloxacin, Lomefloxacin \t sucralfate, sucralfate \n",
      "Sentences: \n",
      "\tMoxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi - minerals in neutral media . \n",
      "\t Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media erythromycin basic media multi minerals neutral media\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Implanon, Implanon \t antiretroviral, antiretroviral \n",
      "Sentences: \n",
      "\tImplanon failure in an HIV - positive woman on antiretroviral therapy resulting in two ectopic pregnancies . \n",
      "\t Implanon failure HIV positive woman antiretroviral therapy resulting ectopic pregnancies\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t antiretroviral, antiretroviral \t Implanon, Implanon \n",
      "Sentences: \n",
      "\tWe present an interesting case of an HIV - positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place . \n",
      "\t present interesting case HIV positive woman antiretroviral therapy having tubal pregnancies separate occasions Implanon place\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfaphenazole, sulfaphenazole \t quinidine, quinidine \n",
      "Sentences: \n",
      "\tFurafylline and sulfaphenazole had no effect , while quinidine appeared to augment precocene I toxicity . \n",
      "\t Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfaphenazole, sulfaphenazole \t precocene I, precocene \n",
      "Sentences: \n",
      "\tFurafylline and sulfaphenazole had no effect , while quinidine appeared to augment precocene I toxicity . \n",
      "\t Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t precocene I, precocene \t precocene I, precocene \n",
      "Sentences: \n",
      "\tThese results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism . \n",
      "\t results suggest rat liver slices reproduce reported vivo biotransformation precocene appropriate model precocene metabolism\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Pantoprazole, Pantoprazole \t clopidogrel, clopidogrel \n",
      "Sentences: \n",
      "\tPantoprazole has a much weaker effect on clopidogrel 's pharmacokinetics and on platelet reactivity during concomitant use . \n",
      "\t Pantoprazole weaker effect clopidogrel 's pharmacokinetics platelet reactivity concomitant use\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t sunitinib, sunitinib \t sunitinib, sunitinib \n",
      "Sentences: \n",
      "\tThis study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs . \n",
      "\t study aimed investigate efficacy single use sunitinib concurrent sequential administration sunitinib docetaxel NSCLC cell lines resistant EGFR TKIs\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t docetaxel, docetaxel \t sunitinib, sunitinib \n",
      "Sentences: \n",
      "\tSunitinib as a single agent exhibits anti - proliferative effects in vitro in NSCLC cell lines with EGFR T790 M and K - ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration . \n",
      "\t Sunitinib single agent exhibits anti proliferative effects vitro NSCLC cell lines EGFR T790 M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t celecoxib, celecoxib \t celecoxib, celecoxib \n",
      "Sentences: \n",
      "\tWe found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells . \n",
      "\t found antagonism celecoxib drugs breast cancer cells MCF7 following incubation schedules celecoxib doxorubicin cell lines combinations HCT116 cells\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t minocycline, minocycline \t fosfomycin, fosfomycin \n",
      "Sentences: \n",
      "\tThe combination of minocycline and fosfomycin can be synergistic against MRSA . \n",
      "\t combination minocycline fosfomycin synergistic MRSA\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Ticlopidine, Ticlopidine \t ketamine, ketamine \n",
      "Sentences: \n",
      "\tTiclopidine treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC(0- ) ) of oral ketamine by 2.4-fold , whereas itraconazole treatment did not increase the exposure to S - ketamine . \n",
      "\t Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC(0- oral ketamine 2.4-fold itraconazole treatment increase exposure S ketamine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ketamine, ketamine \t itraconazole, itraconazole \n",
      "Sentences: \n",
      "\tTiclopidine treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC(0- ) ) of oral ketamine by 2.4-fold , whereas itraconazole treatment did not increase the exposure to S - ketamine . \n",
      "\t Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC(0- oral ketamine 2.4-fold itraconazole treatment increase exposure S ketamine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t norketamine, norketamine \t ketamine, ketamine \n",
      "Sentences: \n",
      "\tThe ratio of norketamine AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the ticlopidine ( P & lt ; 0.001 ) and itraconazole phases ( P = 0.006 ) as compared to placebo . \n",
      "\t ratio norketamine AUC(0- ketamine AUC(0- significantly decreased ticlopidine P lt NUMBER itraconazole phases P = NUMBER compared placebo\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ABT-737, ABT-737 \t DZNep, DZNep \n",
      "Sentences: \n",
      "\tWe also found that Bcl-2 was overexpressed in DZNep insensitive cells , and cotreatment with DZNep and ABT-737 , a Bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells . \n",
      "\t found Bcl-2 overexpressed DZNep insensitive cells cotreatment DZNep ABT-737 Bcl-2 family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t piperacillin, piperacillin \t methylglyoxal, methylglyoxal \n",
      "Sentences: \n",
      "\tDistinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa . \n",
      "\t Distinct synergistic action piperacillin methylglyoxal Pseudomonas aeruginosa\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t piperacillin, piperacillin \t carbenicillin, carbenicillin \n",
      "Sentences: \n",
      "\tResults revealed that the strains were resistant to many drugs at high levels , only piperacillin , carbenicillin , amikacin and ciprofloxacin showed resistances at comparatively lower levels . \n",
      "\t Results revealed strains resistant drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t piperacillin, piperacillin \t amikacin, amikacin \n",
      "Sentences: \n",
      "\tResults revealed that the strains were resistant to many drugs at high levels , only piperacillin , carbenicillin , amikacin and ciprofloxacin showed resistances at comparatively lower levels . \n",
      "\t Results revealed strains resistant drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t methylglyoxal, methylglyoxal \t piperacillin, piperacillin \n",
      "Sentences: \n",
      "\tDistinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects . \n",
      "\t Distinct statistically significant synergism observed methylglyoxal piperacillin disc diffusion tests compared individual effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t dasatinib, dasatinib \t paclitaxel, paclitaxel \n",
      "Sentences: \n",
      "\tHEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone . \n",
      "\t HEY cells treated dasatinib plus paclitaxel formed fewer colonies cells treated agent\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t dasatinib, dasatinib \t paclitaxel, paclitaxel \n",
      "Sentences: \n",
      "\tStudies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib -mediated induction of p27(Kip1 ) enhanced paclitaxel -induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression . \n",
      "\t Studies forced expression siRNA knockdown Bcl-2 Cdk1 suggest dasatinib -mediated induction p27(Kip1 enhanced paclitaxel -induced apoptosis negatively regulating Bcl-2 Cdk1 expression\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, tamoxifen \t SSRI antidepressants, SSRI antidepressants \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, tamoxifen \t paroxetine, paroxetine \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, tamoxifen \t fluoxetine, fluoxetine \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t antidepressant, antidepressant \t tamoxifen, tamoxifen \n",
      "Sentences: \n",
      "\tIf in certain cases , an antidepressant is considered necessary , it may be advisable to replace tamoxifen with anastrozole . \n",
      "\t certain cases antidepressant considered necessary advisable replace tamoxifen anastrozole\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t doxycycline, doxycycline \t MPTP, MPTP \n",
      "Sentences: \n",
      "\tand/or antibiotic drug doxycycline ( 100 mg / kg , p. o. ) , as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( MPTP ) ( 4 x 20 mg / kg , i. p. ) \n",
      "\t and/or antibiotic drug doxycycline NUMBER mg kg p. o. neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine MPTP NUMBER x NUMBER mg kg i. p.\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine \t MPTP, MPTP \n",
      "Sentences: \n",
      "\tand/or antibiotic drug doxycycline ( 100 mg / kg , p. o. ) , as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( MPTP ) ( 4 x 20 mg / kg , i. p. ) \n",
      "\t and/or antibiotic drug doxycycline NUMBER mg kg p. o. neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine MPTP NUMBER x NUMBER mg kg i. p.\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Calcium, Calcium \t nonheme or heme iron iron, nonheme heme iron iron \n",
      "Sentences: \n",
      "\tCalcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron iron at doses less than 800 milligrams in nonpregnant women . \n",
      "\t Calcium inhibit absorption NUMBER milligrams nonheme heme iron iron doses NUMBER milligrams nonpregnant women\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Calcium, Calcium \t heme iron, heme iron \n",
      "Sentences: \n",
      "\tCalcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron iron at doses less than 800 milligrams in nonpregnant women . \n",
      "\t Calcium inhibit absorption NUMBER milligrams nonheme heme iron iron doses NUMBER milligrams nonpregnant women\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t nonheme or heme iron iron, nonheme heme iron iron \t heme iron, heme iron \n",
      "Sentences: \n",
      "\tCalcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron iron at doses less than 800 milligrams in nonpregnant women . \n",
      "\t Calcium inhibit absorption NUMBER milligrams nonheme heme iron iron doses NUMBER milligrams nonpregnant women\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Calcium, Calcium \t heme iron, heme iron \n",
      "Sentences: \n",
      "\tCalcium is the only known component in the diet that may affect absorption of both nonheme and heme iron iron . \n",
      "\t Calcium known component diet affect absorption nonheme heme iron iron\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Calcium, Calcium \t nonheme iron, nonheme iron \n",
      "Sentences: \n",
      "\tCalcium doses 1000 mg diminished nonheme iron absorption by an average of 49.6 % . \n",
      "\t Calcium doses NUMBER mg diminished nonheme iron absorption average NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t calcium, calcium \t heme iron, heme iron \n",
      "Sentences: \n",
      "\tA calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7 % . \n",
      "\t calcium dose NUMBER mg diminished absorption NUMBER mg heme iron NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t calcium, calcium \t nonheme ( as sulfate ) and heme ( as CRBC ) iron, nonheme sulfate heme CRBC iron \n",
      "Sentences: \n",
      "\tIn conclusion , we demonstrated an isolated effect of calcium ( as chloride ) on absorption of 5 mg of iron provided as nonheme ( as sulfate ) and heme ( as CRBC ) iron . \n",
      "\t conclusion demonstrated isolated effect calcium chloride absorption NUMBER mg iron provided nonheme sulfate heme CRBC iron\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t calcium, calcium \t heme ( as CRBC ) iron, heme CRBC iron \n",
      "Sentences: \n",
      "\tIn conclusion , we demonstrated an isolated effect of calcium ( as chloride ) on absorption of 5 mg of iron provided as nonheme ( as sulfate ) and heme ( as CRBC ) iron . \n",
      "\t conclusion demonstrated isolated effect calcium chloride absorption NUMBER mg iron provided nonheme sulfate heme CRBC iron\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t GSLS, GSLS \t inactivated AI vaccines, inactivated AI vaccines \n",
      "Sentences: \n",
      "\tIn experiment 2 , the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines , and an enhanced serum antibody response to AI vaccination was also observed . \n",
      "\t experiment NUMBER regimen GSLS administered chickens inoculated inactivated AI vaccines enhanced serum antibody response AI vaccination observed\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print('We print the baseline first and then the stop words version. Gold relation corresponds to baseline\\n\\n')\n",
    "curr_linenum = 0\n",
    "with open(original_sentences_path) as original_sentences, open(stop_words_sentences_path) as stop_words_sentences:\n",
    "    for x, y in zip(original_sentences, stop_words_sentences):\n",
    "        needed_linenums = list(needed_linenum_and_relation.keys())\n",
    "        if curr_linenum in needed_linenums:\n",
    "            _, e1_b, e2_b, s_b = read_sentence_and_entities(x.strip())\n",
    "            _, e1_c, e2_c, s_c = read_sentence_and_entities(y.strip())\n",
    "            r_b, r_c = needed_linenum_and_relation[curr_linenum]\n",
    "            if r_b == 'int': interaction += 1\n",
    "            elif r_b == 'mechanism': mechanism += 1\n",
    "            elif r_b == 'advise': advice += 1\n",
    "            elif r_b == 'effect': effect += 1\n",
    "            elif r_b == 'none': none += 1\n",
    "            print('Predicted Relation: \\t {0}, {1} \\nEntities: \\t {2}, {3} \\t {4}, {5} \\nSentences: \\n\\t{6} \\n\\t {7}'.format(\n",
    "                    r_b, r_c, e1_b, e1_c, e2_b, e2_c, s_b, s_c))\n",
    "            print('\\n')\n",
    "        curr_linenum += 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "14 52 29 37 135\n"
     ]
    }
   ],
   "source": [
    "print(interaction, mechanism, advice, effect, none)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "267"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "interaction + mechanism + advice + effect + none"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
